| ALABAMA |
Location: Birmingham
University of Alabama at Birmingham-
Division of Preventive Medicine
Trial Title and
Description:
Prevention of
Alzheimer's Disease by Vitamin E and Selenium
(PREADVISE)- The Prevention of Alzheimer's
disease by Vitamin E and Selenium (PREADVISE)
prevention trial is an important addition to the
Selenium and Vitamin E Cancer Prevention Trial
(SELECT). As a prevention trial, PREADVISE is trying
to find out if taking Selenium and/or Vitamin E
supplements can help to prevent memory loss and
dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Isabelle Joffrion
205-934-9502
ijoffrion@dopm.uab.edu
Back
to Top |
Location: Tuscaloosa
Tuscaloosa VA Medical Center- Nursing
Home Care Unit (NHCU)
Trial Title and Description:
Low-Dose Opiate Therapy for
Discomfort in Dementia (L-DOT)-
The
purpose of this study is to determine whether a low
dose of opiate pain medication is effective for the
treatment of discomfort in patients with advanced
dementia. The study medication is also known as Lortab
and contains both a narcotic pain medication and the
same pain medication as contained in Tylenol. The
study will also assess how well patients tolerate this
medication and will measure the impact that relief of
discomfort has on agitation and other symptoms. This
study is an eight-week long clinical trial for
discomfort among veterans with advanced dementia who
are admitted to a Nursing Home Care Unit (NHCU) at the
Tuscaloosa VA Medical Center.
Enrollment Status: Not yet
recruiting
Study Dates: Start: October 2006
Expected Completion: July 2009
Condition: Dementia, Pain,
Alzheimer's disease, Vascular dementia
Age
Eligibility: 55 and above
Gender
Eligibility: Both
Enrollment
Goal: 48
Clinical
Identifier: NCT00385684
Study
Phase: Phase 4
Study Type: Interventional
Sponsor: Department of Veterans
Affairs
Contact Information:
Lori L. Davis
205-554-2000, ext. 3819
Julie R. Wakefield
205-554-2000, ext. 3674
Back
to Top |
| ALASKA |
Location: Anchorage
Alaska
Regional Hospital
Trial Title and
Description:
Prevention of
Alzheimer's Disease by Vitamin E and Selenium
(PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Judith
Link
907-264-1579
judith.link@healthcare.com
Back
to Top |
Location: Anchorage
Providence Alaska Medical Center
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by
Vitamin E and Selenium (PREADVISE) prevention trial is
an important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Kathleen
W. Shue
907-261-3109
kwilsack@provak.org
Back
to Top |
| ARIZONA |
Location: Phoenix
GSK Clinical
Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Adjunctive Therapy to Acetylcholinesterase
Inhibitors In Mild To Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD) when
combined with one of the currently approved AD
medications, Aricept®, Razadyne® or Exelon®. RSG XR is
a new approach to AD therapy and this study tests a
new way to treat AD by testing whether one’s genetic
makeup affects the response to the study drug.
Enrollment Status: Recruiting
Study Dates: Start: July 2006
Condition: Alzheimer's
disease
Age Eligibility: 50-85
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Stephen
Flitman (for zip code 85013)
877-379-3718
Pierre Tariot (for zip code 85006- Not yet
recruiting)
602-239-6920
Jeffrey Gitt (for
zip code 85050)
602-288-4673
Back
to Top |
Location: Phoenix
GSK Clinical
Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Monotherapy In Subjects With Mild to
Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD). RSG XR is a
new approach to AD therapy and this study tests a new
way to treat AD by testing whether one’s genetic
makeup affects the response to the study drug.
Enrollment Status: Not yet
recruiting
Study Dates: Start: January
2007
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Stephen
Flitman
877-379-3718
Back
to Top |
Location: Sun City
GSK Clinical
Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Adjunctive Therapy to Acetylcholinesterase
Inhibitors In Mild To Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD) when
combined with one of the currently approved AD
medications, Aricept®, Razadyne® or Exelon®. RSG XR is
a new approach to AD therapy and this study tests a
new way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Recruiting
Study Dates: Start: July 2006
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Maninder
Kahlon
877-379-3718
Back
to Top |
Location: Tucson
University of
Arizona
Trial Title and Description: Anti-Oxidant Treatment of Alzheimer's
Disease-
The purpose of this study is to examine the safety
and effectiveness of two anti-oxidant treatment
regimens in patients with mild to moderate Alzheimer's
disease. The anti-oxidant treatments include vitamin E
+ C + alpha-lipoic acid, and Coenzyme Q
(CoQ).
Enrollment Status: Recruiting
Study Dates: Start: January
2006
Condition: Alzheimer's
disease
Age Eligibility: 60-85
Gender Eligibility: Both
Enrollment Goal: 75
Clinical Identifier: NCT00117403
Study Phase: Phase
1
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA)
Contact Information:
Marjorie
Baldwin
520-626-4296
baldwinm@u.arizona.edu
Geoffrey Ahern
Back
to Top |
Location: Call for details
Trial Title and Description: A study of V950 in People with
Alzheimer's Disease-
The purpose of this study is to test the safety,
tolerability and immune response to an investigational
vaccine, V950.
Enrollment Status: Recruiting
Study Dates: Start: April 2007
Condition: Alzheimer's
disease
Age Eligibility: 55 and
above
Gender Eligibility: Both
Enrollment Goal: Call for
details
Clinical Identifier: NCT00464334
Study Phase: Phase
1
Study Type: Interventional
Sponsor: Merck
Contact Information:
Trial
Manager
888-577-8839
Back
to Top |
Location: Call for details
Trial Title and Description: Open-Label Extension Assessing Long
Term Safety of Rosiglitazone In Subjects with Mild To
Moderate Alzheimer's Disease-
This is an open-label extension to study 49653/461,
to assess the long-term safety of rosiglitazone
(extended release tablets) in subjects with mild to
moderate Alzheimer's disease.
Enrollment Status: Recruiting
Study Dates: Start: February
2006
Condition: Alzheimer's
disease
Age Eligibility: 50-85
Gender Eligibility: Both
Enrollment Goal: 60
Clinical Identifier: NCT00381238
Study Phase: Phase
2
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
877-379-3718
Back
to Top |
| CALIFORNIA |
Location: Chula
Vista
University of California, San Diego- Chula
Vista
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Clydene Nee
858-622-5747
Back
to Top |
Location: Fresno
GSK Clinical
Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Adjunctive Therapy to Acetylcholinesterase
Inhibitors In Mild To Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD) when
combined with one of the currently approved AD
medications, Aricept®, Razadyne® or Exelon®. RSG XR is
a new approach to AD therapy and this study tests a
new way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Recruiting
Study Dates: Start: July 2006
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
David
Margolin (for zip code 93720)
Justine Kent (for
zip code 93720)
877-379-3718
Back
to Top |
Location: Glendale
Glendale
Memorial Hospital
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August
2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Mary
Eichenhofer
818-409-7653
Back
to Top |
Location: Irvine
University of
California, Irvine
Trial Title and Description: Anti-Oxidant Treatment of Alzheimer's
Disease-
The purpose of this study is to examine the safety
and effectiveness of two anti-oxidant treatment
regimens in patients with mild to moderate Alzheimer's
disease. The anti-oxidant treatments include vitamin E
+ C + alpha-lipoic acid, and Coenzyme Q
(CoQ).
Enrollment Status: Recruiting
Study Dates: Start: January
2006
Condition: Alzheimer's
disease
Age Eligibility: 60-85
Gender Eligibility: Both
Enrollment Goal: 75
Clinical Identifier: NCT00117403
Study Phase: Phase
1
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA)
Contact Information:
Catherine
McAdams-Ortiz
949-824-8726
cmcadams@uci.edu
Ruth Mulnard
Back
to Top |
Location: La Jolla
University
of California, San Diego
Trial Title and Description: Anti-Oxidant Treatment of Alzheimer's
Disease-
The purpose of this study is to examine the safety
and effectiveness of two anti-oxidant treatment
regimens in patients with mild to moderate Alzheimer's
disease. The anti-oxidant treatments include vitamin E
+ C + alpha-lipoic acid, and Coenzyme Q
(CoQ).
Enrollment Status: Recruiting
Study Dates: Start: January
2006
Condition: Alzheimer's
disease
Age Eligibility: 60-85
Gender Eligibility: Both
Enrollment Goal: 75
Clinical Identifier: NCT00117403
Study Phase: Phase
1
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA)
Contact Information:
Mary Pay
858-622-5804
mpay@ucsd.edu
Judith Rivera
858-622-5807
jrivera@ucsd.edu
David Weisman
Back
to Top |
Location: La
Jolla
University of California, San Diego
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by
Vitamin E and Selenium (PREADVISE) prevention trial is
an important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May
2002 Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National
Institute on Aging (NIA), National Cancer Institute
(NCI)
Contact Information:
Clydene Nee
858-622-5747
Back
to Top |
Location: La Mesa
GSK Clinical
Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Monotherapy In Subjects With Mild to
Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD). RSG XR is a
new approach to AD therapy and this study tests a new
way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Not yet
recruiting
Study Dates: Start: January
2007
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Jorge
Porras
877-379-3718
Back
to Top |
Location: Loma
Linda
VA Medical Center
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Kimberly
A. Bluff
909-558-3107
bluffk@lom.med.va.gov
Back
to Top |
Location: Long Beach
VAMC Long
Beach
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Francoise M.
Toussaint-Jones
562-826-5755
Back
to Top |
Location: Los
Angeles
University of California, Los Angeles
Trial Title and Description: Anti-Oxidant Treatment of Alzheimer's
Disease-
The purpose of this study is to examine the safety
and effectiveness of two anti-oxidant treatment
regimens in patients with mild to moderate Alzheimer's
disease. The anti-oxidant treatments include vitamin E
+ C + alpha-lipoic acid, and Coenzyme Q
(CoQ).
Enrollment Status: Recruiting
Study Dates: Start: January
2006
Condition: Alzheimer's
disease
Age Eligibility: 60-85
Gender Eligibility: Both
Enrollment Goal: 75
Clinical Identifier: NCT00117403
Study Phase: Phase
1
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA)
Contact Information:
Jenny Bardens
310-794-6191
jbardens@mednet.ucla.edu
John Ringman
Back
to Top |
Location: Los
Angeles
University of California
Trial Title and Description: Depression in Alzheimer's Disease-
The purpose of this study is to learn whether
treating individuals with Alzheimer's disease and
depression with the anti-depressant medication
Sertraline (Zoloft) is helpful to people with
Alzheimer's disease and to their families and
caregivers.
Enrollment Status: Recruiting
Study Dates: Start: July 2004
Condition: Alzheimer's disease,
Depression
Age Eligibility: 18 and
above
Gender Eligibility: Both
Enrollment Goal: 130
Clinical Identifier: NCT00086138
Study Phase: Phase 2,
3
Study Type: Interventional
Sponsor: National Institute of
Mental Health (NIMH)
Contact Information:
Shirley Sian
323-442-7600
sian@usc.edu
Back
to Top |
Location: Los Angeles
GSK
Clinical Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Monotherapy In Subjects With Mild to
Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD). RSG XR is a
new approach to AD therapy and this study tests a new
way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Recruiting
Study Dates: Start: January
2007
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
David Trader
877-379-3718
Back
to Top |
Location: Newport Beach
GSK
Clinical Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Monotherapy In Subjects With Mild to
Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD). RSG XR is a
new approach to AD therapy and this study tests a new
way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Not yet
recruiting
Study Dates: Start: January
2007
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Philip
O'Carroll
877-379-3718
Back
to Top |
Location: Northridge
Northridge
Hospital Medical Center
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Diane M. Killian
818-885-5458
Back
to Top |
Location: Oceanside
GSK
Clinical Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Monotherapy In Subjects With Mild to
Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD). RSG XR is a
new approach to AD therapy and this study tests a new
way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Not yet
recruiting
Study Dates: Start: January
2007
|
